Cord Blood Stem Cells Do Not “Age”—Under Proper Banking Conditions
Stem Cells Translational Medicine · 2024
DOI: 10.1093/stcltm/szad072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cells Translational Medicine, 2024. Verfasst von Andromachi Scaradavou. Beteiligte Einrichtung: Department of Pediatrics Stem Cell Transplantation and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Cord Blood Stem Cell Transplantation, Adult Stem Cells. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Cord Blood units (CBU) used for allogeneic transplantation are stem cell products that have been collected, fully tested, cryopreserved, and stored in liquid nitrogen freezers in CB Banks. Long-term storage is necessary, as clinical utilization may take place years after collection. Therefore, evaluation of the CB product quality after prolonged storage is critical. To assess the impact of cryopreservation and long-term storage, CB Banks have been performing in vitro studies evaluating CB characteristics such as hematopoietic progenitor cell recovery and potency.1,2 These analyses have now become a requirement for the FDA for CB license,3 and the Foundation for the Accreditation of Cellular Therapy (FACT),4 as well as for European regulatory agencies. The stability evaluation, a comprehensive assessment of CB product integrity, identity, safety, purity, and potency (using the FDA terms)3 aims to address the clinical question of whether CBU cryostorage time affects the ability of the stem cells to engraft and give rise to a new hematopoietic system.1 In regulatory terms, stability assessment determines the product expiration date.3 While CB stability data have been previously reported,1 the most comprehensive publication is included in this issue of STEM CELLS Translational Medicine. The manuscript “Long-term stability of DUS Cord Blood units after 29 years of cryopreservation – Follow-up data from the Jose Carreras Cord Blood Bank”5 presents important quality data for CBU of the specific bank and shows clearly that despite very long storage times (up to 29 years for some CBU), the CB potency characteristics, namely total nucleated cell (TNC) recovery and viability, and CD34+ cell recovery, and viability, remain essentially unchanged, even in the “older” CBU. While these evaluations are performed in vitro, they measure CB attributes that are clinically relevant as they impact patient outcomes. For example, post-thaw CD34+ cell viability, a graft characteristic that has been shown to correlate strongly with engraftment after CB transplantation,6 was very high and remained remarkably stable in the Bank’s evaluations, underscoring that hematopoietic cell quality is not compromised by storage time. In other words, under well-controlled CB manufacturing and storage conditions, we do not see evidence of cell damage or product “decay” (deterioration) in the CB units, at least for the storage times evaluated. The implications of the excellent recoveries and cell viabilities after long-term storage reported by Liedtke et al5 are 2-fold, in my opinion. First, time in cryostorage is not a limitation per se for transplantation of CB products. Therefore, arbitrarily excluding “older” CBU from clinical use based merely on their time in storage is not a data-driven decision, at least for products of those CB Banks that provide stability data for publications or report them to the FDA. Instead, consideration of the various manufacturing aspects (automated vs. manual processing, volume reduction, RBC depletion, freezing, storage in the liquid nitrogen phase, etc.)7 and testing assays (including potency, HLA typing, and infectious disease markers), as they have changed significantly overtime, and their implications for clinical use and patient safety,8 allows for a comprehensive assessment of the CB products, and these are outlined in the recent clinical guidelines for CBU selection.9,10 Furthermore, FDA license and/or CB Bank accreditation by FACT/AABB (Association for the Advancement of Blood and Biotherapies) provide assurance that processes are under control, and CB products are tested as required, including stability evaluations. Moreover, these quality data further support the (financial and scientific) investment in large CB Inventories for current and future use of products. Finally, since stored CBU can be used as starting material for cell therapies, documentation of consistent quality overtime is crucial for optimal selection of products for cell engineering such as the generation of clinical grade CB-derived pluripotent cells (iPSCs).11-13 The second implication is broader, regarding all cell therapies: cryopreservation and long-term storage without cell damage are critical to the development of “off-the-shelf” products.1 While their storage time may vary, the ability to preserve potency/quality remains crucial, particularly since many require extensive manipulation (eg, gene therapy products). Frozen inventories of cell therapy products expedite patient access and clinical use because they are available upon demand; consequently, development of specific criteria for in vitro evaluation of stability and functionality over time becomes an essential consideration for the implementation of new therapies.1 Ideally, laboratory studies would need to correlate with engraftment data. The limited clinical evaluations available in the literature do not support impaired engraftment based on the “age” of the CBU (ie, the time in cryostorage, up to 10 years in the clinical reports).14,15 However, the many variables affecting clinical outcomes and the small patient numbers make this less useful and almost “anecdotal” information. Instead, we need to rely on carefully executed in vitro assessments as these described by Liedtke et al5 that evaluate clinically meaningful CB characteristics. Furthermore, there may still be an argument that the number of stored products tested for stability is overall very small, and more data are needed, preferably for each individual CBU. The CB banking field has addressed that: there is the way to perform quality analysis of products after cryopreservation by using the CBU attached segment, a representative sample of the stored product (bag), and segment results correlate with product measurements post-thaw.1,16,17 The segment potency testing is feasible and has become a standard, routine evaluation of the cryopreserved CB products, required by FACT before release for transplantation. The current manuscript also presents analysis of aliquots (not necessarily segments) of the CBU provided for transplantation, and good correlation of their laboratory measurements with the clinical engraftment data.5 In summary, following the pioneer studies of Hal Broxmeyer testing long-term stored research CB samples for potency/quality (by colony-forming assays) and functionality (by transplants in immunodeficient mice),18 CB banks are performing carefully designed, systematic evaluations of stored clinical CB products that need to meet predetermined acceptance criteria, so that they can provide assurance that the products maintain their quality. The results of the Jose Carreras Cord Blood Bank in Dusseldorf are clinically relevant and add a valuable contribution to the field of cell therapy. None declared. The author declared no potential conflict of interest. No new data were generated or analyzed in support of this research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Pediatrics Stem Cell Transplantation and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID-Profile: Andromachi Scaradavou
Zitieren
APA
Scaradavou, A. (2024). Cord Blood Stem Cells Do Not “Age”—Under Proper Banking Conditions. Stem Cells Translational Medicine. https://doi.org/10.1093/stcltm/szad072
Vancouver
Scaradavou A. Cord Blood Stem Cells Do Not “Age”—Under Proper Banking Conditions. Stem Cells Translational Medicine. 2024. doi:10.1093/stcltm/szad072
BibTeX
@article{Scaradavou2024,
author = {Scaradavou, Andromachi},
title = {Cord Blood Stem Cells Do Not “Age”—Under Proper Banking Conditions},
journal = {Stem Cells Translational Medicine},
year = {2024},
doi = {10.1093/stcltm/szad072}
}
EUVIMED